Kezar Life Sciences
South San Francisco
About Kezar Life Sciences
Kezar Life Sciences company focused on the discovery and development of drugs targeting protein homeostasis for autoimmune disorders. In parallel with this work, Christopher and Kezar co-founder Jack Taunton, Ph.D. collaborated on several research projects involving protein secretion. This collaboration inspired a belief in the strong synergies between protein degradation and protein secretion, two fertile areas for drug discovery with platform potential.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $135.2M
- Funding stage: IPO
- Last round: Post-IPO Equity (Oct 2022)
- Ticker: nasdaq:KZR
- Website: kezarlifesciences.com
- Phone: (650)822-5600
Industries & Categories
Health Care, Health Diagnostics, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/kezar-life-sciences-40137 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.